검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | FLOT |
Overview Company | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
Overview Modality | ANTIBODY |
Overview Target | Gastroesophageal Adenocarcinoma |
Overview Indication | Esophagogastric Adenocarcinoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Biomarker | PD-1 inhibitor plus SOX or PD-1 inhibitor plus FLOT (3-5 cycles) follow |
PK/PD Species | Mouse, Toxicity is manageable across all arms |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Toxicity is manageable across all arms |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Perioperative FLOT Chemotherapy in Resectable Gastric Adenocarcinoma: A Single-center Retrospective Observational Study.. Gastric cancer (GC) is a leading cause of cancer-related mortality worldwide. Perioperative chemotherapy improves tumor downstaging and survival rates. The FLOT regimen was proven superior in the FLOT4-AIO trial, establishing it as the standard care for resectable gastric adeno… |
Clinical PFS | 8.7 |
Clinical OS | 11.8 |
Clinical Result source | ClinicalTrials.gov NCT02735239 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | FLOT |
Overview Company | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
Overview Modality | ANTIBODY |
Overview Target | Gastroesophageal Adenocarcinoma |
Overview Indication | Esophagogastric Adenocarcinoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Biomarker | PD-1 inhibitor plus SOX or PD-1 inhibitor plus FLOT (3-5 cycles) follow |
PK/PD Species | Mouse, Toxicity is manageable across all arms |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Toxicity is manageable across all arms |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Perioperative FLOT Chemotherapy in Resectable Gastric Adenocarcinoma: A Single-center Retrospective Observational Study.. Gastric cancer (GC) is a leading cause of cancer-related mortality worldwide. Perioperative chemotherapy improves tumor downstaging and survival rates. The FLOT regimen was proven superior in the FLOT4-AIO trial, establishing it as the standard care for resectable gastric adeno… |
Clinical PFS | 8.7 |
Clinical OS | 11.8 |
Clinical Result source | ClinicalTrials.gov NCT02735239 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교